Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of estrogen levels on analgesic effect and adverse reactions of biased μ-opioid receptor agonist taglitin
ChiCTR2600130325Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of oliceridine in postoperative pain (4 arms), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoint: SPID 0–24h at rest. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
oliceridine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2600130325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130325.